Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).

Trial Profile

Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms EVIDENCE
  • Sponsors Novartis
  • Most Recent Events

    • 10 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Planned end date changed from 1 Apr 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top